Amgen's Aimovig halved migraine days in 30 pct of trial patients
April 17, 2018 at 16:00 PM EDT
LOS ANGELES, April 17 (Reuters) - A late-stage trial of Amgen Inc's experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday.
